Chimerix

News Releases

2005

Chimerix, Inc. Announces Selection As A Top 5 Nominee For 2005 World Technology Award In Health And Medicine

   

RESEARCH TRIANGLE PARK, NC, November 10, 2005 - Chimerix, Inc., a biotechnology company developing orally available, targeted medicines to treat smallpox and other viral infections, announced today that the company has been selected as one of the top five nominees… > Read More

Chimerix, Inc. Supports Biodefense Legislation to Accelerate and Innovate Counterterrorism Products

   

RESEARCH TRIANGLE PARK, NC, November 3, 2005 - Chimerix, Inc., a biotechnology company developing orally available, targeted medicines to treat smallpox infection and other viral infections, announced today support for S. 1873, the Biodefense and Pandemic Vaccine and Drug Development… > Read More

Chimerix Named a Red Herring Top 100 Private Company

   

 - Award Recognizes Chimerix as a Top Company in North America
that Drives the Technology Industry’s Future -

SAN DIEGO, CA, May 12, 2005 - Chimerix Inc., an emerging biotechnology company developing orally available antiviral therapeutics, today… > Read More

2004

Chimerix Raises $11 Million

   

SAN DIEGO, CA, November 4, 2004 - Chimerix Inc., an emerging biotechnology company developing orally available antiviral therapeutics, today announced an $11 million private placement of its Series C preferred stock. Frazier Healthcare Ventures, a new investor, led the round, and… > Read More

Chimerix Granted Patent for CMX001

   

SAN DIEGO, CA, April 27, 2004 – Chimerix, Inc. and the University of California, San Diego (UCSD) announced today the issuance of U.S. Patent No. 6,716,825 entitled “Phosphonate Compounds” by the U.S. Patent and Trademark Office. The patent claims novel phosphonate… > Read More

Chimerix Awarded NIH Grant

   

SAN DIEGO, CA, March 11, 2004 - Chimerix Inc., a biotechnology company developing orally available, targeted medicines for the treatment of smallpox, multi-drug resistant HIV and hepatitis virus infections, today announced that it has been awarded a Phase I Small Business Innovation… > Read More

2003

Chimerix Announces Licensing Deal

   

- Chimerix Obtains Rights to Cidofovir for Development of an Oral Drug to Treat Smallpox Infections -

SAN DIEGO, CA, September 12, 2003 - Chimerix Inc., an emerging biotechnology company developing orally available, targeted medicines from bioactive molecules, today… > Read More

Chimerix Awarded $36.1m NIH Grant To Develop Its Oral Drug For The Treatment Of Smallpox Infection

   

- Company Also Closes $3.1M Private Equity Financing 

SAN DIEGO, CA, September 9, 2003 – Chimerix Inc., an emerging biotechnology company developing orally available, targeted medicines from bioactive molecules, today announced… > Read More

2002

Chimerix, Inc. Announces Appointment of Expert

   

- Company Currently Developing an Oral Drug for Smallpox Infections

SAN DIEGO, CA, October 9, 2002 - Chimerix, Inc., an emerging biotechnology company developing orally available, targeted medicines from bioactive molecules,… > Read More

 <  1 2 3